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Preservation of peritoneal membrane (PM) is essential for long-term survival in peritoneal dialysis (PD). Continuous presence
of PD fluids (PDF) in the peritoneal cavity generates chronic inflammation and promotes changes of the PM, such as fibrosis,
angiogenesis, and lymphangiogenesis.Mesothelial-to-mesenchymal transition (MMT) and endothelial-to-mesenchymal transition
(Endo-MT) seem to play a central role in this pathogenesis. We speculated that Rapamycin, a potent immunosuppressor, could be
beneficial by regulating blood and lymphatic vessels proliferation. We demonstrate that mice undergoing a combined PD and
Rapamycin treatment (PDF + Rapa group) presented a reduced PM thickness and lower number of submesothelial blood and
lymphatic vessels, as well as decreased MMT and Endo-MT, comparing with their counterparts exposed to PD alone (PDF group).
Peritoneal water transport in the PDF+Rapa group remained at control level, whereas PD effluent levels of VEGF, TGF-𝛽, andTNF-
𝛼 were lower than in the PDF group. Moreover, the treatment of mesothelial cells with Rapamycin in vitro significantly decreased
VEGF synthesis and selectively inhibited the VEGF-C and VEGF-D release when compared with control cells. Thus, Rapamycin
has a protective effect on PM in PD through an antifibrotic and antiproliferative effect on blood and lymphatic vessels. Moreover,
it inhibits Endo-MT and, at least partially, MMT.
1. Introduction
Peritoneal dialysis (PD) is a form of renal replacement ther-
apy based on the ability of the peritoneal membrane (PM) to
perform diffusive and convective transport, in order tomain-
tain solute and fluid equilibrium in uremic patients. Ultrafil-
tration (UF) failure and the consequent extracellular volume
overload are one of the major causes of PD abandonment [1].
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In early stages, membrane damage may manifest itself as
an increase in water and solute transport, but, as the lesion
progresses, transport decreases and underdialysis may take
place. The main factors involved in UF failure are peritoneal
chronic and acute inflammation, which may lead to progres-
sive deterioration of PM function (type-I PM failure).
Glucose degradation products (GDPs), formation of
advanced glycation end-products (AGEs), uremic toxins, and
low pH in PD fluids (PDF) play important roles in PMdeteri-
oration [2].These bioincompatible features of PDFs induce an
immunological response in PM, involving mesothelial cells
(MCs), macrophages, lymphocytes, and neutrophils. They
are stimulated to produce a variety of cytokines and growth
factors, such as tumor necrosis factor- (TNF-) 𝛼, interleukin-
(IL-) 1, IL-8, transforming growth factor- (TGF-) 𝛽, vascular
endothelial growth factor (VEGF), and fibroblast growth
factor- (FGF-) 2, which amplify the inflammation, with struc-
tural and functional consequences [3]. One important conse-
quence of PDFs bioincompatibility is the induction of MCs
transdifferentiation, a phenomenon known as mesothelial-
to-mesenchymal transition (MMT) [4]. Transdifferentiated
cells have been detected in PM even before the onset of
fibrosis [5], a second consequence of PD. They are also
major contributors to VEGF and TGF-𝛽 production in the
peritoneum, providing more stimuli for extracellular matrix
(ECM) production (fibrosis) and enhancement of the local
vascular networks [6], leading to angiogenesis, a third conse-
quence of PD.The result is a thickened and hypervascularized
PM, which leads to the changes in fluid and solute transport
observed in patients in the long term of PD [5, 6]. Another
important process involved in peritoneal pathogenesis is the
endothelial-mesenchymal transdifferentiation (Endo-MT).
Its importance has been recently recognized and between 3 to
5% of submesothelial PD fibroblasts seem to derive from this
process [7]. MMT and Endo-MT share common triggering
mechanisms. Both begin with TGF-𝛽 overproduction and
activation of Smads cascade, leading to VEGF hyperpro-
duction [8, 9]. But VEGF production is not only regulated
by TGF-𝛽; glucose from PDFs per se also induces VEGF
upregulation, as well as vascular hyperpermeability and PD
dysfunction, as has been demonstrated [10]. The implication
of VEGF in both, early and late stages of PM failure (inducing
high vascular permeability and hypervascularization, resp.),
leads us to hypothesize that VEGF may be considered a
therapeutic target. In addition, VEGF hyperproduction leads
to another of the consequences of PD: peritoneal lymphan-
giogenesis, which ismainly regulated byVEGF-C andVEGF-
D and is closely linked to MMT [6, 11]. Although poorly
studied, lymphangiogenesis is one of the most decisive factor
implied in peritoneal water transport disorders [1].
Rapamycin is a macrolide antibiotic produced by Strep-
tomyces hygroscopicus that shows antifungal, immunosup-
pressant, and antitumor properties. Its therapeutic effects are
derived from its ability to inhibit the so-called mammalian
target of rapamycin (mTOR) complex and include antifi-
brotic, cytostatic, antiangiogenic, and anti-lymphangiogenic
effects [12] as has been demonstrated in tumors, especially
carcinomas and hematologic cancers, as well as in retinal and
corneal diseases [13–15]. The same anti-VEGF effect could
also explain the inhibition of lymphangiogenesis showed by
Rapamycin in kidneys [16]. We wondered if this drug could
have an effect over Endo-MT, whichmay be involved in tissue
fibrosis.
Recently, two articles analyzed the antifibrotic effect of
Rapamycin on the PM in a rat PD model [17, 18]. Xu et al.
focused their discussion on the capacity of Rapamycin to
inhibit the extracellular matrix production and to improve
the peritoneal transport [17]. Ceri et al. [18] studied the
regression of peritoneal sclerosis in a rat model of encap-
sulating peritoneal sclerosis (EPS) treated with Rapamycin.
Unfortunately, none of them analyzed the intraperitoneal
antilymphangiogenic effect of this drug.
According to the aforementioned data, we suggest that
the PMdeteriorationmight be treatedwith Rapamycin, given
its pleotropic effects including antiangiogenic, antilymphan-
giogenic, antifibrotic, and anti-inflammatory properties. The
goal of this study was to analyze the effects of Rapamycin on
PM damage in a mice PD model. We also analyzed its effect
on MCs viability, cytokine production, and wound healing
capacity. Herein, we demonstrated that Rapamycin protects
the PM in PD, modulating the tissue fibrosis, MMT, Endo-
MT, and especially angiogenesis and lymphangiogenesis.
2. Materials and Methods
2.1. Peritoneal Dialysis Fluid Exposure Model in Mice. A total
of 21 female C57BL/6 mice aged between 12 and 16 weeks
were used in this study (Harlan Interfauna Iberica, Barcelona,
Spain). The experimental protocol used was in accordance
with the National Institutes of Health Guide for Care and
Use of Laboratory Animals and was approved by the Animal
Ethics Committee of the “Unidad de Cirugı´a Experimental”
of “Hospital Universitario la Paz.” Food and water were
provided ad libitum to the animals.
PDF or saline was instilled via a peritoneal catheter
connected to a subcutaneous mini access port (Access Tech-
nologies, Skokie, IL, USA) as previously described [7, 19].
During the first week after surgery, the animals received
0.2mL of saline with 1 IU/mL heparin. Thereafter, during a
4-week period, 6 mice did not receive any treatment (control
group), 7 mice were daily instilled with 2mL of standard PD
fluid (PDF group) composed of 4.25% glucose and buffered
with lactate (Stay Safe; Fresenius, Bad Homburg, Germany),
and 7mice were treated with oral Rapamycin diluted in water
(2mg/kg/day in 15 𝜇L of volume administered to mice using
a pipette and a gastric tube) and daily instilled with 2mL of
standard PD fluid (PDF + Rapamycin group).
Two animals of the PDF group and one from PDF +
Rapamycin group were not used in the final analysis, because
of catheter port infections related to skin wounds (control
group, 𝑛 = 6; PDF group, 𝑛 = 5; and PDF + Rapamycin
group, 𝑛 = 6). A peritoneal equilibrium test was performed
in the last day of experiment. For this purpose, all mice
were instilled with 2mL of PD solution (dextrose 4.25%).
After 30min, they were anaesthetized with isoflurane (MTC
Pharmaceuticals, Cambridge, ON, Canada) and sacrificed, so
that all the peritoneal fluid volume that remained in the cavity
could be recovered, as previously described [7, 19, 20]. Briefly,
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thismethod consists of opening the peritoneal cavity through
an incision in the muscle and extracting all the fluid with a
pipette. There is always a minimum percentage of remaining
volume that is not possible to extract.
Diaphragmatic and parietal peritoneum samples were
obtained from the contralateral side of the implanted catheter.
2.2. Histological Analyses of Peritoneal Samples and Efflu-
ent Growth Factors Measurements. For histological analysis,
parietal peritoneum from the opposite side to the catheter
insertion site was divided into several pieces, avoiding the
linea alba. One piece was directly frozen in OCT (optimal
cutting temperature) compound for immunofluorescence
analysis and two other pieces were routinely fixed in Bouin
or neutral buffered 3.7% formalin and embedded in paraffin
to obtain 5𝜇m tissue sections.
Deparaffinized sections from Bouin fixed samples were
stained with Masson’s trichrome. The submesothelial thick-
ness was determined in a blinded manner, by microscope
analysis and the mean of independent measures every 60 𝜇m
was considered for each animal.
For immunohistochemical studies, diaphragmatic and
peritoneal tissue samples previously fixed in neutral buffered
3.7% formalin were cut into 3 𝜇m sections and heated to
expose the hidden antigens using Real Target Retrieval Solu-
tion containing citrate buffer, pH 6.0 (Dako, Glostrup, Den-
mark). Samples were also pretreated with Real Peroxidase-
Blocking Solution (Dako) to block endogenous peroxidase.
A biotinylated goat IgG (H + L) (Vector Laboratories,
Burlingame, CA, USA) was applied to detect primary anti-
bodies CD31 (Abcam, Cambridge, UK) and podoplanin
(PA2.26, a gift from Dr. Gamallo, Laboratory of Pathology,
Hospital de La Princesa, Madrid, Spain). Complexes were
visualized by R.T.U Vectastain Elite ABC Kit (Vector Labora-
tories) and usingDAB (Dako) as chromogen. Finally, all cases
were counterstained with haematoxylin. In order to estimate
the vessel density, 6 arbitrary 20x fields in the submesothelial
peritoneal area were analyzed and quantified using the scale
barmethod (numbers of CD31+ cells/𝜇m2). Images were ana-
lyzed by computerized digital image analysis (AnalySIS, Soft
Imaging System). Number of cells with single or double pos-
itive staining was counted and was expressed as the mean of
10 independent measurements for each animal. Podoplanin
positive lymphatic vessels in the diaphragms of 6 arbitrary 10x
fields for each animal were quantified using the analysis pro-
gram Image-J 1.37c (National Institute of Health, Bethesda,
Maryland).
For immunofluorescence analysis, cryostat sections
(5 𝜇m) from frozen samples were stained with antibodies
to visualize vasculature (CD31; Serotec, Oxford, UK), MCs
(Pan-Cytokeratin; Sigma-Aldrich), and pathologic fibroblasts
(FSP1; Dako). The sections were fixed for 15 minutes in 4%
formaldehyde in PBS and blocked with 10% horse serum for
1 hour in PBS with 0.3% Triton X-100. First antibodies were
incubated in PBS with 0.1% Triton X-100 overnight at 4∘C.
After 3 washing steps, secondary Alexa-labelled antibodies
were incubated for 90 minutes at room temperature. After
another washing process, the preparations were mounted
with a 4,6-diamidino-2-phenylindole (DAPI) nuclear stain
(Vectashield; Vector Laboratories). Negative controls for
immunofluorescence staining were conducted using 10%
rabbit serum instead of primary antibody. The cytokeratin
and FSP-1 costaining defined the MMT and the CD31 and
FSP1 costaining defined the Endo-MT.
The amounts of VEGF-A, TGF𝛽1, and TNF-𝛼 in peri-
toneal effluent were obtained the last day of experiment (PET
day) and determined by ELISA-based assays, according to
manufacturers’ instructions (BMS619, Bender MedSystems,
Vienne, Austria; DY1679, R&D Systems, Minneapolis, USA;
and 560478, BD Company, BS, San Jose´, CA, USA, resp.).
2.3. Differences in Peritoneal UF Rate among Mice Exposed
to PD versus Controls. In order to analyze the changes in
water peritoneal transport between peritoneum exposed to
PD and virgin peritoneums, a separate study was performed:
twenty mice with virgin peritoneum (control group) received
an intraperitoneal injection of 2mL of Stay Safe 4.25% (Fre-
senius Medical Care). These mice were sacrificed extracting
the total water volume from peritoneal cavity at 20, 30,
40, and 60 minutes after intraperitoneal injection (UF test).
Another twenty mice were subjected to PD receiving and
intraperitoneal infusion of Stay Safe 4.25%, 2mL per day,
during 30 days. At the end of the experiment we performed
the same UF test. Five mice were analyzed in each time point
(20, 30, 40, and 60min) for both groups.
2.4. Culture ofOmentumandEffluent-DerivedMCs andTreat-
ments. MCs were obtained from omental samples of patients
undergoing elective abdominal surgery and from peritoneal
effluents of PD patients as previously described [21]. These
cells were cultured in Earle’s M199 medium supplemented
with 20% fetal calf serum, 50U/mL penicillin, 50𝜇g/mL
streptomycin, and 2% Biogro-2 (containing insulin, transfer-
rin, ethanolamine, and putrescine: Biological Industries, Beit
Haemek, Israel). The purity of omentum- and effluent-
derived MCs cultures was determined by the expression of
standard mesothelial markers: intercellular adhesion mole-
cule- (ICAM-) 1, calretinin, and cytokeratins. These MCs
cultures were negative for von-Willebrand factor and CD45,
ruling out any contamination by endothelial cells or macro-
phages [21]. To induce MMT in vitro, omentum-derived
MCs were initially seeded in bottle flash (25 or 100mL) and
then plated at P6 (50.000 cells/mL in M199 medium, Bauer
Chamber). When they reached subconfluence, MCs seeded
onwells coated with collagen I (50𝜇g/mL, RocheDiagnostics
GmbH, Mannheim, Germany) and treated in different time
points (6 to 48 hours) with human-recombinant TGF-𝛽1
(1 ng/mL, R&D Systems Inc., Minneapolis, MN, USA),
a commonly used in vitro model of MMT [21]. Where
indicated, Rapamycin (Wyeth Laboratories, Madison,
NJ, USA) was administered at concentrations of 2 and
4 nM. Effluent-derived MCs that had undergone MMT
(as determined by nonepithelioid morphology, by low
expression of E-cadherin, and by upregulated expression of
mesenchymal markers) were also treated with different doses
of Rapamycin (2, 4, and 20 nM) and analyzed at 6, 24, and 48
hours. In order to establish a correction factor we measured
the total protein in each well at the end of the experiment.
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The present study adjusts to the Declaration of Helsinki
and it was approved by the Ethics Committee of “Hospital
Universitario de la Princesa” (Madrid, Spain). Informed
written consent to use effluent samples was obtained from
all the PD patients included in this study and oral informed
consent was obtained from omentum donors subjected to
elective surgeries.
2.5. Western Blot, Quantitative RT-PCR, and Enzyme-Linked
Immunoassays. For western blotting, MCs cultures were
lysed in a buffer containing 1% sodiumdeoxycholate and 0.1%
sodium dodecyl sulfate (SDS). Total protein was quantified
using a protein assay kit (Bio-Rad, Hercules, CA). Total cell
protein (50𝜇g) was resolved on 8–10% SDS-polyacrylamide
gels and transferred to nitrocellulosemembranes, whichwere
then blocked with fat-freemilk and probed with specific anti-
bodies against E-cadherin, 𝛼-SMA, collagen I, fibronectin,
and tubulin (Sigma-Aldrich, Inc., St. Louis, MO). These
antibodies were detected with peroxidase conjugated goat
anti-mouse IgG antibody (BD Biosciences, Franklin Lakes,
NJ) and visualized by enhanced chemiluminescence (ECL
detection kit, Amersham Biosciences, Freiburg, Germany).
Images of the blots were acquired with an LAS-1000 Charge
Coupled Device camera (Fujifilm, Cedex, France).
For quantitative RT-PCR analysis, MCs were lysed in TRI
Reagent (Ambion Inc., Austin, TX), and RNA was extracted
as fabricant instructions. Complementary-DNA was syn-
thesized from 2 𝜇g of total RNA by reverse transcription
(RNA PCR Core Kit, Applied Biosystems Inc., New Jersey).
Quantitative PCR was carried out in a Light Cycler 2.0 using
a SYBR Green Kit (Roche Diagnostics GmbH) and specific
primers sets for Snail, E-cadherin, and histone H3. Samples
were normalized with respect to the value obtained for H3.
The primer sets employed for Snail, E-cadherin, and H3 have
been previously described [7].
VEGF-A, VEGF-C, and VEGF-D were measured in the
culture supernatants by ELISA kits (R&D Systems Inc.,
USA): VEGF-A, catalog number DVE00 and sensitivity
9 pg/mL; VEGF-C, catalog number DVEC00 and sensitivity
48.4 pg/mL;VEGF-D, catalog numberDVED00 and sensitiv-
ity 31.3 pg/mL. For all of them, the cross-reactivity observed
with available related molecules was <0.5%.
2.6. Proliferation Assays. For proliferation assays, 104 cells/
well of omentum derived MCs with epithelioid phenotype
(semiconfluent) were seeded into 96-well plates and cultured
at 37∘C, 5% CO
2
and incubated with Rapamycin 2, 4, and
20 nM for 48 hours. Cells were then pulsed with [3H]-
thymidine (1mCi per well) for 16–18 hours and lysed with
Filter Mate Cell Harvester (Perkin Elmer, Turku, Finland).
Radioactivity was determined for 1 minute in a basic beta
liquid scintillation counter (Perkin Elmer).
As a complementary cell proliferation test and using the
same experimental conditions as the previous assay, we also
measured total protein synthesis (𝜇g/mL) using Pierce, BCA
protein assay kit (Life Technologies, USA).
2.7. Cell Cycle and Wound Healing. To analyze the effect
of Rapamycin on cell cycle profile, omentum MCs were
grown in fetal calf serum and treated with different doses of
Rapamycin (2, 4, and 20 nM) for 48 h. Cells were trypsinized,
pelleted, and fixed with 70% cold ethanol for 30min. After
washing, samples were suspended in PBS and an equal
volume of propidium iodide solution, containing 200𝜇g/mL
RNase (Sigma Aldrich), 20 𝜇g/mL propidium iodide (Sigma
Aldrich), and 0.1% Triton X-100 in PBS, was added to the cell
suspension for 30min at room temperature. A FACS Calibur
flow cytometer (BD Bioscience) was used to analyze DNA
content; emitted light was measured at 675 nm.
To test the effect of Rapamycin on MCs wound repair
capacity, a wound healing experiment was performed with
cells treated or not with different doses of Rapamycin. Briefly,
MCs from omentum, treated or not with Rapamycin, were
subjected to mechanical injury with an adapted cell scraper
approximately 1500𝜇m in width and photographed every
eight hours during 72 hours. MCs treated with high doses of
Rapamycin showed a slight delay at 24 and 48 hours inwound
closure.
2.8. Statistical Analysis. Data from animal experiments and
effluent parameters were compared with one-way ANOVA
test and nonparametric Mann–Whitney rank sum 𝑈 test
(Figures 1–5). In vitro experiments were performed in trip-
licate. One representative WB picture was taken from each
case and quantified using bar graphics (Figures 6 and 7). The
cell proliferation and cell cycle experiments were repeated
in five occasions (Figures 7(b) and 7(c)). We used the SPSS
statistic package version 14.5 (Chicago, IL) and GraphPad
Prism version 4.0 (La Jolla, CA). 𝑝 < 0.05 was considered
statistically significant. Box plot graphics represent the 25th
and 75th percentiles and median, minimum, and maximum
values (Figures 1–5 and 7).
3. Results
3.1. Rapamycin Ameliorated Peritoneal MembraneThickening,
Fibrosis, and MMT Induced by Dialysis Fluid Exposure in
a Mouse PD Model. We analyzed whether Rapamycin, an
mTOR inhibitor with recognized antifibrotic effect [12],
might prevent the deterioration of the PM in a mouse model
of PDF exposure. Histological analysis of parietal peritoneum
biopsies from animals exposed to PDF (PDF group, 𝑛 = 5)
showed a loss ofMCsmonolayer and increased PM thickness
when compared to control mice, which preserved the MCs
monolayer (control group, 𝑛 = 6). Oral administration
of Rapamycin (2mg/kg/day) to PDF-treated mice (PDF +
Rapamycin group, 𝑛 = 6) significantly reduced the peritoneal
thickness (Figure 1(a)).Then, we analyzed the contribution of
MMT to the number of submesothelial fibroblasts and fibro-
sis during PD. Figure 1(b) shows the immunofluorescence
staining of cytokeratin (red) and FSP-1 (green) (counter-
stained with DAPI in blue). The PDF exposure-promoted
MMT (cells coexpressing cytokeratin and FSP-1 with double
positive staining, yellow) is reduced by Rapamycin admin-
istration. Importantly, PDF group shows many costained
MCs (yellow) in superficial areas (arrows) suggesting that
MMT occurs at early stages of MCs transdifferentiation
before invading the submesothelial area. PM thickness (𝜇m)
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Figure 1: Rapamycin decreases the PM deterioration in a PD mouse model. Mice received a daily instillation of standard PD fluid (2mL
per day) through a intraperitoneal catheter during 4 weeks with or without the oral administration of Rapamycin (2mg/kg/day: PDF, 𝑛 = 5,
and PDF + Rapamycin, 𝑛 = 6). A control group of mice that were only exposed to the presence of the catheter was also included (control;
𝑛 = 6). Peritoneal samples were prepared and analyzed as described in Materials and Methods section. (a) Standard PD fluid exposure
increases matrix deposition (blue stained zones) and the thickness of the PM (black lines), while Rapamycin administration significantly
reduces these effects when measured in Masson’s trichrome staining (sections representative slides). Magnification 200x. (b) As shown in
immunofluorescence staining of cytokeratin (red) and FSP-1 (green) (counterstained with DAPI in blue), PDF exposure-promoted MMT
(cells coexpressing cytokeratin and FSP-1 with double positive staining, yellow) is reduced by Rapamycin administration. Magnification
400x. (c) The peritoneal thickness (𝜇m) is increased in PDF group compared with control mice, and the group PDF with Rapamycin shows
a significant reduction of thickness when compared with PDF group. Analysis of variance results in a significance of 𝑝 = 0.001 (one-way
ANOVA test). (d) Measurement of TGF-𝛽1 (pg/mL) in the drained volumes shows a gentle increase (although not statistically significant) of
this growth factor in PD fluid-instilled animals while Rapamycin administration tends to reduce TGF-𝛽1 production.The analysis of variance
results in a 𝑝 value of 0.146 (one-way ANOVA test). (e) Numbers ofmesothelial cells per field sufferingMMT increase during PDF exposition,
while Rapamycin is able to reduce the occurrence of this pathological process. The analysis of variance results in a significance of 𝑝 < 0.0001
(one-way ANOVA test). Box plots graphics represent the median, minimum, and maximum values, as well as the 25th and 75th percentiles.
Numbers above boxes depict means ± SE. Symbols represent the statistical differences between groups analyzed by Mann-Whitney 𝑈 test.
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Figure 2: Treatment with Rapamycin decreases PD-induced angiogenesis and Endo-MT. Mice received a daily instillation of standard PD
fluid with or without the oral administration of Rapamycin (PDF; 𝑛 = 5 and PDF + Rapamycin; 𝑛 = 6). A control group of mice was also
included (control; 𝑛 = 6). (a) Standard PD fluid exposure increases peritoneal angiogenesis and Rapamycin administration significantly
reduces the number of submesothelial blood vessels, as determined by CD31 staining (number of CD31+ cells/𝜇m2). Magnification 200x. (b)
Standard PD fluid exposure also increases the presence of endo-MMT, measured as double positive immunofluorescence staining (white
arrows) of CD31 (green) and FSP-1 (red) (counterstained with DAPI, in blue), which is reduced by Rapamycin administration. Magnification
200x. (c) Box plots represent the number of submesothelial CD31+ vessels stained cells per field in the different experimental groups and
show a decrease of angiogenesis in the Rapamycin-treated animals. The analysis of variance results in a significance of 𝑝 < 0.0001 (one-way
ANOVA test). (d) The numbers of double stained CD31+/FSP-1+ cells per field increase in the PDF-exposed group and show a decrease in
the Rapamycin-treated animals. The one-way ANOVA test resulted in a significance of 𝑝 < 0.0001. Box plots graphics represent 25th and
75th percentiles and median, minimum, and maximum values. Numbers above boxes depict means ± SE. Symbols represent the statistic
differences between groups.
increased in PDFgroup comparedwith controlmice andPDF
+Rapamycin group. Figure 1(c) shows the statistic differences
between the groups after a double blind count of PM thick-
ness in ten arbitrarily chosen fields of optical microscopy.
Since TGF-𝛽 is themajor inducer ofMMT and tissue fibrosis,
we measured its levels in PD effluent. We found statistically
significant differences between control group and PDF group,
which showed maximum levels. Rapamycin group showed
low TGF-𝛽, which did not reach statistical significance
(Figure 1(d)). Figure 1(e) shows the count ofMCs, which have
sufferedMMT. Given that PM thickness usually runs parallel
to the MMT, Rapamycin showed less transdifferentiated
MCs, as expected. These differences were statistically signifi-
cant.
3.2. Rapamycin Decreased PD-Induced Angiogenesis and
Endo-MT. Angiogenesis is an important process that occurs
in the PM during PD [22], and a robust antiangiogenic
effect of Rapamycin has been described in other tissues [12].
This drug acts by decreasing VEGF production or blocking
its receptors [23]. To test the effect of Rapamycin on PDF-
induced angiogenesis, blood vessels of the parietal peri-
toneumwere stained with an anti-CD31 antibody. In the peri-
toneum from control mice, CD31 expression was confined
to deeper vessels located in the muscular tissue (Figure 2(a))
while the PDF group showed a significant increase in the
number of submesothelial vessels in comparison with PDF +
Rapamycin group.
Although Endo-MT is a poorly known phenomenon in
PD, it may contribute to PM fibrosis. Figure 2(b) shows CD31
and FSP1 costaining in the submesothelial compact zone.
Again, the PDF group showed more costained cells (yellow,
see arrows) than the other groups. Figure 2(c) shows the sta-
tistically significant differences between the groups in angio-
genesis rate (submesothelial CD31+ vessels) and Figure 2(d)
shows the number of endothelial cells suffering Endo-MT
(CD31+ and FSP1+). Rapamycin group showed less MCs
transdifferentiation than PDF group but similar to controls.
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Figure 3: Treatment with Rapamycin diminished lymphangiogenesis, improving peritoneal ultrafiltration rate. (a) The diaphragm was
stained with podoplanin to analyze the side of the peritoneal cavity. Immunohistochemical staining of podoplanin reveals an increase of
submesothelial lymphatic vessels during PDF exposition, while this lymphangiogenesis is reduced with Rapamycin. Images were taken with
a 10x objective. Insets below show a detail of the part selected with a square in each picture. (b) Submesothelial count of lymphatic vessels
(podoplanin positive staining). Rapamycin showed significantly lower number of lymphatic vessels than the PDF group and similar to controls
(𝑝 = 0.0002, one-way ANOVA test). (c) A 30-minute UF test was performed on the last day of treatments. The volumes recovered from
animals exposed to PD fluid are lower than those from control mice and an increase of net UF is obtained in mice exposed to PD fluid that
were administrated Rapamycin. A significance of 𝑝 = 0.0064 was obtained with the analysis of variance test.
3.3. Rapamycin Decreased PD-Induced Lymphangiogenesis
and Improved Peritoneal Ultrafiltration Rate. Lymphangio-
genesis is another anatomical change associated with type-I
PM failure. In PD, this process is poorly studied and seems to
be closely related to the peritoneal water transport. In renal
cancer, Rapamycin has been able to inhibit lymphangiogene-
sis, thus delaying the progression of this neoformative process
[16]. Herein, we explore the effect of Rapamycin on lymphatic
vessels formation in a PD mice model. Figure 3(a) shows
the immunohistochemical staining of podoplanin, revealing
an increase of diaphragmatic lymphatic vessels during PDF
exposition. Podoplanin stains MCs, so we can see two MC
layers, one in contact with the pleura and the other thickened,
facing the peritoneal cavity (magnification 10x). Amplifying
the picture, we can see in the PDF group a dramatic increase
in lymphatic vessels number (arrows). The number of these
lymphatic vessels in Rapamycin-treated mice was similar
to controls (Figure 3(b)). At the end of the experiment, we
measured the UF rate. The PDF group presented an altered
UF capacity in comparison to controls or Rapamycin group.
These differences were statistically significant (Figure 3(c)).
Finally, we found that the number of blood and lymphat-
ics vessels at the end of the experiment showed a significant
linear correlation (𝑟2 = 0.78, 𝑝 < 0.001), suggesting that both
phenomena are in parallel (data not shown).
3.4. Rapamycin Decreased VEGF and TNF-𝛼 Levels in PD
Effluent of PD. Treatment with Rapamycin decreased VEGF
in the mice PD effluent (Figure 4(a)). This is consistent
with our previous results showing that Rapamycin decreased
angiogenesis and lymphangiogenesis. We also measured the
effect of Rapamycin on inflammatory markers in the peri-
toneal cavity. To assess the peritoneal inflammatory state, we
measured proinflammatory cytokines levels and the number
of total cells in the PD effluent. Our results indicated that
Rapamycin showed statistically significant lower amounts of
TNF-𝛼 than that of the PDF group. Although we did not find
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Figure 4: Rapamycin decreases VEGF and TNF-𝛼 levels in the peritoneal cavity. (a) Analysis of VEGF and (b) TNF-alpha in the drained
volumes shows a strong increase of these factors in PD fluid-instilled animals, and administration of Rapamycin significantly reduces their
production. The one-way ANOVA test resulted in a significance of 𝑝 < 0.0038 and 𝑝 < 0.0001, respectively. (c) Total numbers of cells in
the drained effluent do not show statistical differences between groups. Box plots graphics represent 25th and 75th percentiles and median,
minimum, and maximum values. Numbers above boxes depict means ± SE. Symbols represent the statistic differences between groups.
significant differences in the total cells number between the
groups (Figures 4(b) and 4(c)), an anti-inflammatory effect
may be defended.
3.5. Rapamycin Decreased VEGF Production by Human Peri-
toneal MCs, Mainly Those with Prolymphogenic Effects. In
PD, angiogenesis and lymphangiogenesis are two crucial
factors involved in peritoneal transport, which are generally
parallel to peritoneal fibrosis [24, 25]. Rapamycin is consid-
ered an anti-VEGF agent; therefore we explored its effect on
VEGF-A, VEGF-C, and VEGF-D production by human peri-
toneal MCs. We isolated and cultivated MCs from omentum
and PD effluent which were stimulated with Rapamycin 2 nM
during 48 h. Both groups showed and important decrease
in VEGF-A, VEGF-C, and VEGF-D supernatant levels espe-
cially the last two which are considered as prolymphogenic
forms (Figures 5(a) and 5(b)). Figure 5(c) shows the same
data expressed in rate of decrease (%) of VEGF-A, VEGF-C,
and VEGF-D decrease.
3.6. Rapamycin Attenuated MMT in PD Effluent and Omen-
tum Derived MCs. Recent studies suggest that Rapamycin
can have total or partial effect on MMT [26, 27]. For this
reason we design the present experiment. We isolated and
cultivated MCs from omentum and PD effluent, which were
stimulated during 48 h with Rapamycin and/or rTGF-𝛽 to
induce MMT. MCs were lysed and proteins extracted for
analysis by WB.
Omentum-derived MCs were cotreated with Rapamycin
and TGF-𝛽. These did not show E-cadherin repression and
had the Fibronectin and Collagen-I upregulation avoided,
features of theMMTprocess (Figure 6(a)). Bar graphics show
the measurement of the different gene expressions (Figures
6(b)-6(c)).
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Figure 5: Rapamycin decreases the VEGF production by MCs. Omentum and PD effluent derived MCs were cultured and stimulated with
Rapamycin 2 nM during 48 h. We performed two parallel cultures with equal numbers of MCs. A group received Rapamycin while the other
was untreated. Supernatants were collected and VEGF-A, VEGF-C, and VEGF-D were measured. Rapamycin significantly decreased VEGFs,
mainly the prolymphopenic VEGF-C and VEGF-D forms (a and b). We also calculated the reduction rate (%). Importantly in nonepithelioid
MCs derived from PD effluent, VEGF-D was reduced by 82% and VEGF-C (gray bar graphic) by 63%. In omentum-derived MCs (white
bar) the VEGF-D and VEGF-C were reduced by 63% and 20%, respectively (c). Box plots graphics represent 25th and 75th percentiles and
median, minimum, and maximum values. Statistical differences between groups are shown (mean ± SD).
Figures 6(e)–6(h) show effluent derived MCs exposed
to Rapamycin during 48 h. Rapamycin decreased 𝛼-SMA,
collagen-I, fibronectin, and tubulin expression, suggesting
that this drug not only reduces ECM but also decreases
cellular protein synthesis in a dose-dependent manner
(Figure 6(e)).
3.7. Rapamycin Blocked Cellular Proliferation and Protein Syn-
thesis and Delayed Wound Heading. Given that Rapamycin
downregulates tubulin expression, we wondered if this is
due to a decrease in cell proliferation, decrease in protein
synthesis, or cell death by toxicity or apoptosis. First, we con-
firmed that the decrease in tubulin expression was time- and
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Figure 6: Rapamycin partially inhibits the MMT of MCs. (a–d) Omentum-derived MCs were treated or not with 1 ng/mL of TGF-𝛽1 for
24 or 48 hours, in the presence of different doses of Rapamycin (2 and 4 nM). (a) Western blot analyses show that Rapamycin treatment
prevents TGF-𝛽1-induced E-cadherin downregulation as well as collagen I and fibronectin. (b) The E-cadherin expression was analyzed at
24 hours, whereas the expressions of (c) collagen-I and (d) fibronectin were analyzed at 48 hours of treatments. (e–h) Effect of Rapamycin
on nonepithelioid phenotype MCs isolated from PD effluent (e) WB analysis in the presence of different Rapamycin’s doses. Rapamycin
inhibited the expression of (f) 𝛼-SMA, (g) Collagen-I, and (h) fibronectin expression in a dose-dependent manner (2, 4, and 20 nM). Results
are presented relative to untreated MCs (black bars) which were arbitrarily assigned as value 1 (b to d and f to h). The experiments were
repeated at least three times and results are depicted as means ± SE (bar graphics).
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Figure 7: Rapamycin partially inhibited theMCs protein synthesis andMCs proliferation. (a) Rapamycin inhibits the tubulin expression in a
time- and dose-dependent manner as shown in theWestern blots analyses and their quantification graphics. Results are presented relative to
untreatedMCs (black bars) which were arbitrarily assigned as value 1. (b) MCs proliferation and (c) protein synthesis omentum cells cultured
in semiconfluence.The first box represents baselineMCs (zero time). Second box shows the natural increases inMCs proliferation and protein
synthesis at 48 h. The rest of the boxes show the decrease in both variables after the Rapamycin administration in a dose-dependent manner.
In (b) and (c), one-way ANOVA analyses show a𝑝 value of𝑝 < 0.001 and𝑝 < 0.0001, respectively. Box plots represent themedian, minimum,
and maximum values, as well as the 25th and 75th percentiles.
dose-dependent (Figure 7(a)). Figure 7(b) shows the normal
proliferation rate of MCs in subconfluence after 48 h in
culture. This normal cell proliferation rate was blocked by
Rapamycin, to levels even lower than those obtained in
controls. A similar situation occurred with cell protein syn-
thesis. When we analyzed the cell cycle (Table 1), Rapamycin
increased the rate of MCs in resting (M1) and apoptosis (M4)
and decreased MCs dividing DNA (M2). This effect also
showed a dose-dependent pattern.
Supplementary Figure 2 in SupplementaryMaterial avail-
able online at http://dx.doi.org/10.1155/2015/989560 shows
the effect of time in culture and Rapamycin doses over cell
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viability. Both factors decreased MCs life rate, but, in the
worst case, dead MCs rate never exceeded 10%.
Given these results, we decided to explore the effect of
Rapamycin over wound healing (WH). To close a wound it is
necessary to maintain an adequate rate of cell proliferation,
cell migration, and reproduction. As expected, Rapamycin
delays WH to 72 hours showing again dose-dependent
pattern (Supplementary Figure 3).
4. Discussion
In PD, type-I PM failure is characterized by progressive
peritoneal thickening, inflammation, angiogenesis, and lym-
phangiogenesis, which ends in severe peritoneal fibrosis and
peritoneal transport failure of water and solutes, shortening
PM usefulness [24, 28].
To prevent PM damage, the main arrangement adopted
so far has been to improve PDF biocompatibility (neutral
pH or low GDPs).The administration of steroids, Tamoxifen,
and some immunosuppressive drugs has become popular
[29]. After promising results in animal and in vitro stud-
ies, the use of Rosiglitazone, COX
2
inhibitors (celecoxib),
Statins, and anti-TGF-𝛽 molecules (among others) has been
proposed [30, 31]. In many cases, the rationale for using
these agents was MMT inhibition. MMT is responsible for
a great number of submesothelial fibroblasts derived from
transdifferentiatedMCs, which perpetuate peritoneal fibrosis
and also angiogenesis and lymphangiogenesis [3, 6], since
these cells are active VEGF producers [10, 22]. As our results
demonstrate, transdifferentiated MCs showed up to 10 times
greater VEGF production than nontransdifferentiated MCs
[6]. Clinically, it has been accepted that the composition of
PDFs,with high content of glucose,GDPs, the osmolarity, low
pH, and the formation of AGEs appear as the major inducers
for VEGF release, directly or indirectly through the synthesis
proinflammatory cytokines [2, 3, 24].
To our knowledge, few studies have consideredVEGF as a
therapeutic target for type-I PM failure preventing strategies.
Rapamycin has traditionally been considered as an inhibitor
of VEGF synthesis [12] and some successful clinical and
animal experiences in treating EPS have been published
[18, 32]. Herein, we present evidences for using Rapamycin
as an antifibrotic and antiproliferative agent for blood and
lymphatic vessels in PM failure.
Either after an acute (peritonitis) or chronic (long-term
PDFs exposure) peritoneal aggression, a physiologic auto-
controlled cellproliferation process occurs. However, in some
cases this autocontrol is lost, leading to peritoneal fibrosis.
The antifibrotic effect of mTOR inhibitors can be explained
by a direct effect on cell cycle [33]. Rapamycin increases the
rate ofMCs in resting, apoptosis, and dead rate, and decreases
MCs dividing DNA, as evidenced by our results (Table 1).
Similarly, Xue et al. [23] demonstrated that Rapamycin binds
the FK-binding protein 12, resulting in a complex that leads
to phosphorylation and inactivation of p70S6 kinase, which
normally has a stimulatory function in the production of
ribosomal components necessary for protein synthesis and
cell cycle, resulting in cell cycle arrest in G1 phase [33, 34].
Table 1: Effect of Rapamycin on cell cycle on MC (%gated).
Cell cycle Control TGF-𝛽 Rapa 2 nM Rapa 4 nM Rapa 20 nM
(M1) 75.77 76.34 78.97 79.74 79.98
(M2) 5.81 3.96 3.41 2.95 2.68
(M3) 15.01 16.19 13.93 13.36 13.22
(M4) 3.41 3.42 3.69 3.75 4.12
Tulek et al. [35] demonstrated that, in pulmonary fibrosis,
the antifibrotic effect of Rapamycin can be explained by an
anti-inflammatory effect mediated by a decrease in IL-13 and
platelet-derived growth factor- (PDGF-) A and TGF-𝛽1 and
an increase in interferon- (IFN-) 𝛾 levels in bronchoalveolar
lavage fluid. Our results are in agreement with these find-
ings, as Rapamycin decreased TNF-𝛼 and TGF-𝛽 in mice
peritoneal effluent (Figure 4). We also found that Rapamycin
treatment diminished the PM cellular infiltration.
Another anti-fibrotic pathway of Rapamycin is the partial
or total inhibition of MMT. In normal conditions, TGF-𝛽1
induces MMT through Smads dependent and independent
pathways [36, 37]. Recently, Patel et al. [26] demonstrated
that Rapamycin inhibited Smad-3 signalling, blockingMMT,
and tissue peritoneal fibrosis in a PD mice model. During
MMT, TGF-𝛽 activates mTORC1 (one of the two functionally
distinct complexes in whichmTOR is present).This results in
an increase in protein synthesis, cell size, motility, and inva-
sion. This translational regulation complements the Smad-
dependent transcriptional regulation induced by TGF-𝛽. The
mTORC2 complex phosphorylates Akt, thus contributing to
its activation, but its exact role in TGF-𝛽-induced MMT
remains to be discovered [38, 39].
Gao et al. [40] suggested that the protectivemechanism of
Rapamycin is Slug- andAkt/mTOR-dependent. Furthermore,
the inhibition of cellular migration by metalloproteinase-
(MMP-) 2 and MMP-9 blockade played a crucial role as
antifibrotic and anti-MMT.
If we understand MMT as a physiological tissue repair
process that needs an activeMC cycle and active proliferation
and migration, the effects of Rapamycin on both processes
would delay tissue repair, but considering that in type-I
PM failure peritoneal repair is uncontrolled and the process
exerts an excessive proliferation, we could speculate that
Rapamycin, used for short periods, could be a therapeutic
alternative.
Another important anatomical change suffered by the PM
inPD is submesothelial angiogenesis [6]. Although angiogen-
esis is supposed to participate in water peritoneal transport
disorders, to our knowledge, it has never been considered as a
therapeutic target itself. Our results indicate that Rapamycin
inhibited the VEGF synthesis in vitro and in vivo. Conse-
quently much less angiogenesis and lymphangiogenesis were
found in the mice treated with PDF alone (Figure 2). In this
group, peritoneal transport was altered compared to con-
trols or Rapamycin-treated animals (Figure 3(c)). Another
mechanism this drug has been related to is an inhibition of
angiogenesis and fibrosis by HIF1𝛼 blockade [41]. However,
we did not analyze this pathway in the present study.
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Recent studies have shown that, in several fibrosing
diseases, endothelial cells can also suffer a mesenchymal
transdifferentiation (Endo-MT), generally commanded by
similar signaling as MMT [8].The importance of this process
is given by its contribution to tissue fibrosis [42]. Herein,
we found important evidence of submesothelial Endo-MT in
PDF group, while in PDF + Rapamycin group this process
was practically nonexistent (Figure 2).
Recently, Zhang et al. [43], using bleomycin to induce in
vitroEndo-MT inHUVECs cells, observedmTOR activation,
and Rapamycin reduced the rate of Endo-MT via Slug inhi-
bition. Effectively, we observed preservation of E-cadherin
and inhibition of Snail upregulation by Rapamycin, in MC
cultures treated or not with TGF-𝛽. Although in this study
we only quantified Snail, both transcription factors (Snail
and Slug) are intimately involved in the induction of the
transdifferentiation process [42].
On the other hand our results indicate that Rapamycin
inhibited the prolymphangiogenic VEGFs forms inMCs cul-
tures. Lymphangiogenesis is a scarcely studied process in PD
and its involvement in PD functional disorders has recently
been recognized [25]. Generally, the lymphatic proliferation
operates in parallel with fibrosis and MMT and its principal
inductor is possibly TGF-𝛽. TGF-𝛽 is activated in the peri-
toneal cavity by PDFs, AGEs, glucose, and proinflammatory
cytokines [4] and is able to induce MMT, Endo-MT, fibrosis,
and VEGF production (which induces blood and lymph
vessels proliferation) [24]. In early stages of type-I PM failure,
proliferation of both types of vessels could be responsible for
hyperfiltration. In fact, in end-stages, when water and solute
peritoneal transport fails, VEGF-C and podoplanin kept their
overexpression in peritoneal tissue [25, 44].
Excessive lymphatic fluid drainage from the abdominal
cavity can also raise concerns because of its potential role over
macromolecule and isosmotic solutions reuptake, as well as
convective reabsorption of solutes that were already cleared
from plasma by diffusion [1, 45]. Our results show that the
PDF group presented higher counts of blood and lymph
vessels, which is normally associated with hyperfiltration.
However, this group showed a lower UF rate (Figure 3(c)).
This apparent contradiction is explained by the moment
UF capacity was measured, because of the changing water
transport speed during the dwell. This change is due to
the functional alterations presented in the PM in the PDF-
treated group (Supplementary Figure 1). Recently, Morelle et
al. used fluorescent albumin and fluorescence spectroscopy
to monitor the UF capacity of the PM in mice lacking the
Aquaporin 1 (AQP1) (a water channel) [46]. Using this model
they conclude that lymphatic absorption occur later, after
30 minutes of fluorescent marker intraperitoneal injection.
However, this study was performed in mice with virgin
peritoneum. With our data we cannot conclude that the
maximumUF, which occurs early in the PDF group, could be
caused by peritoneal lymphatic absorption; nevertheless, we
can confirm that the anatomical changes (angiogenesis and
fibrosis) in our mice after 30 days in PD play a key role in the
peritoneal water transport.
Regarding the antilymphangiogenic mechanism of Rapa-
mycin, we focused on the VEGFs forms levels and found
that VEGF-C and VEGF-D decreased with Rapamycin treat-
ment. Recently, Zheng et al. [11] demonstrated that normally
the lymphatic proliferation starts with P13/AKT activation,
which activates the mTOR pathway. The mTOR blockade
(Rapamycin) acts through a dual effect, inhibiting this com-
plex and interfering with VEGF-Receptor-3 and VEGF-C
intracellular signaling [28, 47].
5. Conclusion
Rapamycin protected the PM through an antifibrotic and
antiproliferative effect on blood and lymphatic vessels. It also
inhibited Endo-MT and at least partially theMMT. Although
this drug has been shown to delay the MCs proliferation,
migration, cell cycle, and wound healing, by slowing peri-
toneal tissue repair, our results suggest that Rapamycin, given
for short periods, could be beneficial to treat early stages of
type-I PM failure.
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